Merck, Bristol-Myers Sued Over Diabetes Drugs' Cancer Risks

Law360, Chicago (June 18, 2013, 4:04 PM EDT) -- Merck & Co. Inc., a Bristol-Myers Squibb Co. subsidiary and Eli Lilly & Co. were all targeted by a New York product liability suit Friday alleging they concealed a link between certain diabetes drugs currently under regulatory investigation and the risk for pancreatic cancer.

Robert and Catherine Cataletto say the companies have continued to promote Merck's Janumet and Januvia oral medications and Bristol Meyers unit Amylin Pharmaceuticals LLC's Byetta injection — for which Eli Lilly acted as a sales agent, according to the plaintiffs — even...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.